PCDH9

PCDH9 is a δ1-protocadherin that functions as both a synaptic organizer in the brain and a context-dependent tumor suppressor in multiple cancer types. In the hippocampus, PCDH9 localizes to glutamatergic synapses where it constrains synapse size; Pcdh9 knockout mice display oversized presynaptic terminals and postsynaptic densities, increased mEPSC amplitude, reduced hippocampal network activity, dysregulation of the SHANK2/CORTACTIN pathway, and behavioral deficits in social and object recognition memory (PMID:39557582, PMID:25802080). PCDH9 undergoes MMP-dependent, activity-driven proteolytic cleavage that releases its intracellular domain (ICD) for nuclear translocation, where the ICD interacts with DNMT1 to hypermethylate and silence CDH2, suppressing cell migration, and separately promotes dendritic growth and spine formation (PMID:38357662, PMID:41685090). PCDH9 protein levels are regulated by COP1- and RNF145-mediated Lys48-linked ubiquitination and proteasomal degradation, and its expression is epigenetically silenced via promoter methylation and miRNA-mediated repression in glioma, hepatocellular carcinoma, and other cancers, where restoration of PCDH9 inhibits proliferation, invasion, and induces apoptosis (PMID:35084653, PMID:41613811, PMID:28791409, PMID:24214103).

1. 1998 Medium

   Establishing PCDH9 as a novel brain-enriched protocadherin resolved its identity within the cadherin superfamily and revealed developmentally regulated expression, setting the stage for functional studies.

   Evidence Genomic cloning, expression profiling across tissues and developmental stages

   PMID:9787079

   Open questions at the time

   • No functional data; expression pattern alone does not establish mechanism
   • Protein-level validation not performed
   • No loss-of-function or gain-of-function experiments
2. 2013 Medium

   Demonstrating that PCDH9 re-expression suppresses glioma cell viability, induces apoptosis, and arrests the cell cycle established PCDH9 as a candidate tumor suppressor and identified Bax/Bcl-2/cyclin D1 as downstream effectors.

   Evidence Lentiviral PCDH9 re-expression in U87/U251 glioma lines with viability, apoptosis, cell cycle, and invasion assays; Western blot

   PMID:24214103

   Open questions at the time

   • Single lab, no in vivo validation
   • Direct versus indirect regulation of Bax/Bcl-2 not distinguished
   • Mechanism linking a cell-adhesion molecule to apoptotic signaling unknown
3. 2015 High

   Pcdh9 knockout mice revealed that the gene is required for normal sensory cortex development and cognitive memory, providing the first in vivo loss-of-function evidence for a non-redundant neurological role.

   Evidence Pcdh9 KO mice generated via QTL-guided targeting; behavioral testing (social/object recognition, rotarod, sensory gating) and neuroanatomical analysis

   PMID:25802080

   Open questions at the time

   • Synaptic and circuit-level mechanisms underlying behavioral deficits unresolved
   • Contribution of cell-autonomous versus non-autonomous functions unknown
   • No electrophysiological characterization
4. 2017 Medium

   Discovery that the PCDH9 promoter is silenced by DNA methylation in HCC and that miR-215-5p represses PCDH9 via both promoter and 3′UTR binding in glioma established convergent epigenetic and post-transcriptional mechanisms for PCDH9 downregulation in cancer.

   Evidence Promoter methylation analysis and 5-azacytidine rescue in HCC; dual-luciferase reporter assays confirming miR-215-5p binding to PCDH9 promoter and 3′UTR in glioma

   PMID:28055966 PMID:28791409

   Open questions at the time

   • Whether promoter methylation and miRNA repression act cooperatively in the same tumor type untested
   • Upstream signals driving methylation not identified
   • In vivo validation of miRNA-mediated repression lacking
5. 2022 High

   Identification of COP1 as an E3 ligase that mediates Lys48-linked polyubiquitination and proteasomal degradation of PCDH9 revealed a post-translational mechanism controlling PCDH9 protein turnover in glioma.

   Evidence Yeast two-hybrid screen, reciprocal co-immunoprecipitation, K48-linkage-specific ubiquitination assay, proteasome inhibitor rescue, clinical correlation in glioma tissues

   PMID:35084653

   Open questions at the time

   • Degron motif on PCDH9 recognized by COP1 not mapped
   • Whether COP1-mediated degradation occurs in neurons unknown
   • Relationship to PCDH9 cleavage-dependent signaling unaddressed
6. 2024 High

   Demonstrating that the PCDH9 intracellular domain translocates to the nucleus and activates DNMT1 to silence CDH2 by promoter hypermethylation established a direct signaling pathway from PCDH9 cleavage to transcriptional reprogramming that suppresses metastasis.

   Evidence Subcellular fractionation, co-immunoprecipitation of ICD with DNMT1, DNMT1 activity assay, bisulfite sequencing of CDH2 promoter, in vivo metastasis assay in gastric cancer models

   PMID:38357662

   Open questions at the time

   • Protease responsible for ICD release not identified in this study
   • Whether DNMT1 interaction occurs in neurons not tested
   • Genome-wide targets of PCDH9-ICD/DNMT1 beyond CDH2 unknown
7. 2024 High

   Comprehensive characterization of Pcdh9 KO hippocampus resolved the synaptic phenotype: PCDH9 localizes to glutamatergic synapses and constrains synapse ultrastructure, with its loss causing enlarged synapses, increased mEPSC amplitude, reduced network activity, and SHANK2/CORTACTIN pathway dysregulation.

   Evidence Immunofluorescence, electron microscopy, single-nucleus RNA-seq, patch-clamp electrophysiology, and biochemical analysis in Pcdh9 KO mice

   PMID:39557582

   Open questions at the time

   • Whether PCDH9 acts trans-synaptically or cell-autonomously at the synapse not fully resolved
   • Binding partner on the presynaptic side unknown
   • Rescue experiments to confirm cell-autonomy not performed
8. 2026 Medium

   Identification of MMP-dependent, activity-triggered cleavage of PCDH9 at synapses, with the resulting CTF promoting dendritic growth and spine density, unified the proteolytic processing observed in cancer with a physiological activity-dependent signaling function in neurons.

   Evidence Biochemical fractionation, MMP inhibitor treatment, CTF overexpression with morphological and electrophysiological readouts in neuronal cultures

   PMID:41685090

   Open questions at the time

   • Specific MMP isoform responsible not identified
   • Whether CTF nuclear targets in neurons overlap with DNMT1/CDH2 pathway unknown
   • Single lab; independent replication needed
9. 2026 Medium

   RNF145 was identified as a second E3 ubiquitin ligase that ubiquitinates and degrades PCDH9 in hepatocellular carcinoma, providing a cancer-type-specific post-translational silencing mechanism.

   Evidence Co-immunoprecipitation, Western blot, transwell migration and wound-healing assays with RNF145 knockdown in HCC cells

   PMID:41613811

   Open questions at the time

   • Ubiquitin chain linkage type not specified
   • Whether RNF145 and COP1 target overlapping or distinct pools of PCDH9 unknown
   • In vivo validation of RNF145-PCDH9 axis lacking

• Key unresolved questions include the identity of the specific extracellular binding partners of PCDH9 at synapses, the genome-wide transcriptional targets of the nuclear ICD beyond CDH2, the structural basis for PCDH9 homophilic or heterophilic interactions, and whether the ICD-DNMT1 signaling axis operates in neurons to link synaptic activity to epigenetic remodeling.
• No structural model for PCDH9 extracellular domain interactions
• Genome-wide targets of ICD/DNMT1 complex not mapped
• Trans-synaptic binding partner unidentified